1. CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. This activity is supported by educational grants from Amgen, Ariad, Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals.

2. Rovalpituzumab Tesirine in R/R SCLC: Study Background  Recurrent SCLC is frequent and has a poor prognosis –Topotecan only FDA-approved agent for recurrent SCLC –No biomarker-directed therapies  DLL3: atypical inhibitory Notch ligand –Aberrantly expressed on surface of > 80% SCLCs –Not expressed on surface of normal adult tissue  Rovalpituzumab tesirine: a novel antibody–drug conjugate targeting DLL3 –Anti-DLL3 mAb (SC16) linked to PBD dimer toxin  First-in-human phase I study evaluated safety and activity in SCLC with progression following first or second line therapy Rudin CM, et al. ASCO 2016. Abstract LBA8505. Slide credit: clinicaloptions.comclinicaloptions.com

3. Rovalpituzumab Tesirine in R/R SCLC: Phase I Study Design  N = 74 SCLC pts progressed after ≥ 1 systemic therapy  Dose-escalation design evaluated rovalpituzumab tesirine 0.05-0.8 mg/kg for Q3W or Q6W –DLTs (decreased platelets, LFT abnormalities) observed at 0.8 mg/kg Q3W –Cumulative toxicity (serosal effusions) observed at 0.4 mg/kg Q3W –Expansion cohorts: 0.2 mg/kg Q3W, 0.3 mg/kg Q6W –RP2D established at 0.3 mg/kg Q6W x 2, with retreatment at progressive disease –0.2-0.4 mg/kg active doses pooled for current analysis Rudin CM, et al. ASCO 2016. Abstract LBA8505. Slide credit: clinicaloptions.comclinicaloptions.com

4. Rovalpituzumab Tesirine in R/R SCLC: Baseline Characteristics CharacteristicPts (N = 74) Median age, yrs (range)61 (38-81) Female, %43 ECOG PS 0/1/2, %28/68/4 Extensive disease, %76 History of CNS metastasis, %28 Response to first-line therapy, %  Sensitive  Resistant  Refractory  Not evaluable 53 31 9 7 Median treatment-free interval, mos (range)4.1 (0.2-89.1) 1/2 prior lines of therapy, %53/47 Tumor DLL3 expression (n = 48), %  ≥ 1% of tumor cells  ≥ 50% of tumor cells 88 67 Slide credit: clinicaloptions.comclinicaloptions.com Rudin CM, et al. ASCO 2016. Abstract LBA8505.

5. Rovalpituzumab Tesirine in R/R SCLC: Treatment-Emergent Adverse Events Treatment-Emergent AE, %All GradesGrade ≥ 3 Individual treatment-emergent AE in ≥ 15% of pts  All  Fatigue  Pleural effusion  Peripheral edema  Nausea  Hypoalbuminemia  Thrombocytopenia  Maculopapular rash  Decreased appetite 88 35 31 27 19 18 16 38 4 8 3 0 11 3 0 Group events with highest grade 3 incidence  Thrombocytopenia  Serosal effusions*  Skin reaction 20 35 49 12 11 8 Slide credit: clinicaloptions.comclinicaloptions.com Rudin CM, et al. ASCO 2016. Abstract LBA8505. *Included pleural or pericardial effusion, ascites, or “capillary leak syndrome” (serosal effusions, peripheral edema, and/or hypoalbuminemia).

6. Rovalpituzumab Tesirine in R/R SCLC: Response Rates Response, % All Pts* Pts With ≥ 50% DLL3 Expression* Investigator (n = 60) IRC (n = 56) Investigator (n = 26) IRC (n = 26) ORR18163931 CBR68648985 Slide credit: clinicaloptions.comclinicaloptions.com Rudin CM, et al. ASCO 2016. Abstract LBA8505. Response, % All Pts* Pts With ≥ 50% DLL3 Expression* 2nd-line Tx (n = 32) 3rd-line Tx (n = 28) 2nd-line Tx (n = 14) 3rd-line Tx (n = 12) ORR13252950 CBR72648692 *Evaluable pts receiving active doses of rovalpituzumab tesirine (0.2-0.4 mg/kg).

7. Rovalpituzumab Tesirine in R/R SCLC: OS Rudin CM, et al. ASCO 2016. Abstract LBA8505. Slide credit: clinicaloptions.comclinicaloptions.com Survival Outcomes All Pts (N = 68) Pts With ≥ 50% DLL3 Expression (n = 29) Median OS, mos4.65.8 1-yr OS, %1832

8. Rovalpituzumab Tesirine in R/R SCLC: Conclusions  Rovalpituzumab tesirine showed favorable single-agent activity in R/R SCLC –Efficacy enhanced against tumors with high (ie, ≥ 50%) DLL3 expression –Similar response rates in second and third line –Response rates, survival markedly improved vs standard therapy  Safety profile deemed manageable by study investigators  Pivotal phase II registrational trial in third line for DLL3- expressing R/R SCLC currently enrolling (NCT02674568)  First line trials planned in DLL3-expressing SCLC, solid tumors (NCT02709889), and in combination with immunotherapy Rudin CM, et al. ASCO 2016. Abstract LBA8505. Slide credit: clinicaloptions.comclinicaloptions.com

9. Go Online for More CCO Coverage of ASCO 2016! Short slideset summaries of all the key data Additional CME-certified analyses with expert faculty commentary on all the key studies in:  Breast, genitourinary, and lung cancers  Hematologic malignancies  Immunotherapy clinicaloptions.com/oncology